Personalis (PSNL) Earnings Date & Reports

Key Takeaways

• Personalis is expected to report third-quarter 2026 results after market close, with consensus calling for a net loss of about $0.26 per share.
• Wall Street projects revenue near $21.5 million, up sharply from $14.5 million in the same quarter a year earlier.
• Investors will focus on growth in minimal residual disease (MRD) testing, a genomic tool that detects tiny amounts of remaining cancer after treatment.
• The pending acquisition of Personalis by Tempus AI at $16.25 per share remains a central driver of how the stock trades around the report.
• Company guidance for full-year 2026 revenue stands at $78 million to $80 million, implying roughly 26% growth.
• For more context on the ticker, review its Major News, Today's Price Move, Price Targets, and Forecast on additional pages.
• Explore Trending AI Robots to discover AI-driven trading strategies and market signals.

Earnings Context and Why It Matters

Personalis is a precision oncology company that develops advanced genomic testing for cancer, with a strategic focus on MRD (minimal residual disease) detection. The company has been deliberately shifting away from lower-margin enterprise work toward higher-value MRD testing, a move management expects to reshape both revenue mix and profitability. This quarter matters because it will show whether that transition is translating into durable growth and improving margins. The report also arrives against an unusual backdrop: a pending agreement for Tempus AI to acquire Personalis at $16.25 per share. That transaction looms over the quarter, making operational results and any commentary on deal timing as important to investors as the headline numbers themselves.

Earnings Expectations

Analysts expect Personalis to report a net loss of approximately $0.26 per share for the third quarter of 2026, according to consensus estimates. That compares with a loss of $0.24 per share in the same period a year ago. On the top line, the consensus revenue estimate is about $21.5 million, which would represent roughly 48% growth from $14.5 million in the prior-year quarter. In its most recent report for the second quarter of 2026, Personalis posted a loss of $0.30 per share, slightly wider than the $0.26 consensus, while revenue of about $22.4 million beat expectations. For the full 2026 fiscal year, management has guided to revenue of $78 million to $80 million, with biopharma MRD revenue expected to more than double year over year.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking companies like Personalis, it can surface emerging opportunities across the precision medicine and genomics space.

Market Reaction and Investor Sentiment

Heading into the release, sentiment around Personalis is shaped more by the pending Tempus AI acquisition than by quarterly fundamentals alone. The stock has climbed roughly 64% over the past year and trades near the $16.25 per-share offer price, suggesting investors are positioning for deal completion. With a beta of about 2.3, Personalis remains significantly more volatile than the broader market, meaning any surprise on results or deal commentary could trigger outsized price moves. Key risk factors include a wider-than-expected loss, softer MRD demand, or any sign of friction in the acquisition process. A strong quarter, by contrast, could reinforce confidence in the company's standalone growth trajectory even as the merger moves forward.

Forward Outlook and Key Factors to Monitor

Beyond the headline figures, investors should watch several forward-looking signals. First, growth in biopharma MRD revenue is the clearest indicator of whether the company's strategic pivot is working. Management has signaled this segment should more than double year over year, so any shortfall would draw scrutiny.

Second, gross margin trends matter. Recent quarters showed margin compression as the company invested strategically and shifted its revenue mix. Commentary on Medicare reimbursement expansion for clinical testing and how it affects margins will be closely read.

Third, the pending Tempus AI acquisition remains the dominant catalyst. Any update on regulatory approvals, closing timelines, or integration plans will likely outweigh near-term operating results for many investors. Finally, watch the company's cash position, which remains substantial at more than $200 million, providing runway to fund continued investment in MRD testing even while the deal proceeds.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations